Research Paper Volume 16, Issue 6 pp 5676—5702
Identification and validation of a novel signature based on macrophage marker genes for predicting prognosis and drug response in kidney renal clear cell carcinoma by integrated analysis of single cell and bulk RNA sequencing
Figure 12. The role of IFI30 in KIRC. (A) Pan-cancer analysis of IFI30 expression in human tumors. (B) Expression of IFI30 in KIRC and para-cancerous tissues in TCGA database. (C) Expression of IFI30 in KIRC and normal tissues in TCGA database. (D) IFI30 was highly expressed in KIRC cell lines compared to normal renal tubular epithelial cell line (HK-2). (E, F) RT-qPCR and Western blot were used to verify the interference efficiency of IFI30 in A498 and 786-O cells. (G) CCK8 assay. (H) Transwell assay. (I) Colony formation assay. (J) Wound healing assay. (K) EdU staining assay. Error bars are mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001.